[
    [
        {
            "time": "2018-03-15",
            "original_text": "Big Pharma to testify in Senate drug pricing hearing",
            "features": {
                "keywords": [
                    "Pharma",
                    "Senate",
                    "drug pricing",
                    "hearing"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 10,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 10,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-02-12",
            "original_text": "Novartis In-Licenses Rights to Heart Candidate From Ionis",
            "features": {
                "keywords": [
                    "Novartis",
                    "Ionis",
                    "Heart Candidate",
                    "In-Licenses"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-03-01",
            "original_text": "Roche (RHHBY) to Acquire Spark Therapeutics for $4.8 Billion",
            "features": {
                "keywords": [
                    "Roche",
                    "Spark Therapeutics",
                    "Acquire",
                    "$4.8 Billion"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-02-13",
            "original_text": "Novartis aims to pump up cardio business with Ionis deal",
            "features": {
                "keywords": [
                    "Novartis",
                    "cardio",
                    "business",
                    "Ionis",
                    "deal"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-03-04",
            "original_text": "Roche bets $4.3 bln on Spark in gene therapy move",
            "features": {
                "keywords": [
                    "Roche",
                    "Spark",
                    "gene therapy",
                    "$4.3 bln"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-02-15",
            "original_text": "Detailed Research: Economic Perspectives on Novartis AG, Proteostasis Therapeutics, Williams-Sonoma, Magna International, YRC Worldwide, and Delek Logistics Partners â€” What Drives Growth in Today's Competitive Landscape",
            "features": {
                "keywords": [
                    "Research",
                    "Economic Perspectives",
                    "Novartis",
                    "Proteostasis",
                    "Growth"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "retail",
                    "industrial",
                    "logistics"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-02-14",
            "original_text": "Novartis licenses rights to RNA-targeting cardio drug from Ionis",
            "features": {
                "keywords": [
                    "Novartis",
                    "RNA-targeting",
                    "cardio",
                    "drug",
                    "Ionis"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-03-05",
            "original_text": "[$$] Stocks to watch: Persimmon, General Electric, Centamin, Spark",
            "features": {
                "keywords": [
                    "Stocks",
                    "watch",
                    "Persimmon",
                    "General Electric",
                    "Centamin",
                    "Spark"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "real estate",
                    "industrial",
                    "mining",
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 5,
                "Sentiment": 4,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 4
            }
        }
    ]
]